Summary
This Form 8-K filing by Medtronic plc (MDT) on July 17, 2015, primarily serves to provide supplemental pro forma financial information. This information is in anticipation of a registration statement on Form S-4 for debt securities. The pro forma statements reflect the significant acquisition of Covidien, which became a subsidiary of Medtronic plc on January 26, 2015, following a transaction agreement from June 15, 2014. The filing includes unaudited pro forma condensed consolidated statements of income for the fiscal year ended April 24, 2015, giving effect to this transformative acquisition. For investors, this filing is crucial for understanding the financial impact of the Covidien acquisition. The pro forma financial data allows for a more informed view of Medtronic's combined revenue and profitability as if the acquisition had occurred at the beginning of the reported fiscal year. This is essential for evaluating the scale and potential synergies of the merged entity and for assessing the ongoing financial health and future prospects of Medtronic post-acquisition, particularly concerning the newly registered debt securities.
Key Highlights
- 1Medtronic plc filed a Form 8-K on July 17, 2015, to provide supplemental pro forma financial information.
- 2The pro forma financial information relates to the acquisition of Covidien, which became a subsidiary of Medtronic plc on January 26, 2015.
- 3The filing is in preparation for registering debt securities issued by Medtronic, Inc. and guaranteed by Medtronic plc and Medtronic Global Holdings S.C.A.
- 4Unaudited pro forma condensed consolidated statements of income for the fiscal year ended April 24, 2015, are included.
- 5These statements reflect the financial impact of the Covidien acquisition as if it had occurred at the beginning of the fiscal year.
- 6The transaction agreement for the Covidien acquisition was dated June 15, 2014.
- 7Gary L. Ellis, Executive Vice President and Chief Financial Officer, signed the report.